NT 219

Drug Profile

NT 219

Alternative Names: NT219

Latest Information Update: 04 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hebrew University of Jerusalem
  • Developer TyrNovo
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Insulin receptor substrate protein inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Neurodegenerative disorders

Most Recent Events

  • 01 Nov 2017 Kitov Pharmaceuticals plans a phase I/II trial for NT 219 in Pancreatic cancer (Late stage disease; Combination therapy) in 2019
  • 01 Nov 2017 Kitov Pharmaceuticals announces intention to submit IND to US FDA for Cancer in first half of 2019
  • 10 Feb 2017 Kitov announces intention to submit IND to US FDA for NT 219
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top